Our previous work showed the presence of endothelin-1 (ET-1) receptors, ET A and ET B , in human vascular endothelial cells (hVECs). In this study, we wanted to verify whether ET-1 via the activation of its receptors ET A and/or ET B (ET A R and ET B R respectively) play a role in the survival of hVECs. Our results showed that treatment of hVECs with ET-1 prevented apoptosis induced by genistein, an effect that was mimicked by treatment with ET B R specific agonist IRL1620. Furthermore, blockade of ET B R with the selective ET B R antagonist A192621 prevented the anti-apoptotic effect of ET-1 in hVECs.
D r a f t

ROLE OF ENDOTHELIN-1 AND ITS RECEPTORS ET A AND ET B IN THE SURVIVAL OF HUMAN VASCULAR ENDOTHELIAL CELLS.
The vascular endothelium forms a continuous monolayer of cells lining the inner vascular wall (Mudrovcic et al. 2017) . This type of cell presents a large surface area for molecule exchange between the blood and tissues (Baldwin and Thurston 2001) . The endothelial cells respond to chemical and physical stimuli by synthesizing and releasing a variety of vasoactive substances (Cines et al. 1998; Triggle et al. 2012; Mudrovcic et al. 2017) . The equilibrium between these substances is necessary for the regulation of vascular tone (Shepro and D'amore 1984; Triggle et al. 2012; Radenkovic et al. 2016) . Among the most important vasoconstrictors secreted by the endothelium is endothelin-1 (ET-1) (Yanagisawa et al. 1988) . ET-1 mediates its physiological actions via two types of Gprotein coupled receptors namely ET A receptors (ET A Rs) and ET B receptors (ET B Rs) (Arai et al. 1990; Sakurai et al. 1992; Avedanian et al. 2010; Houde et al. 2016 ). Both ET A and ET B receptors are reported to be present in vascular smooth muscle cells (VSMCs) and are mainly responsible for the vasoconstrictor effects of endothelin-1 (Davenport and Maguire 1994; Sudjarwo et al. 1993; Bigaud and Pelton 1992; Cristol et al. 1993; Bkaily et al. 2011 Bkaily et al. , 2015 . Both types of ET-1 receptors were reported to be present in human vascular (Avedanian et al. 2010) and endocardial endothelial (Abdel-D r a f t cell types including human and pulmonary arterial smooth muscle cells, glioma cell lines and rat aortic endothelial cells, ET B R (not ET A R) is anti-apoptotic (Shichiri et al. 1997; De Miguel et al. 2017; Sakai et al. 2016; Paolillo et al. 2010) . As for ET B Rs, the role of ET A Rs in cell survival is also controversial (Shichiri et al. 1997; Ren et al. 2008; De Miguel et al. 2017 , Maffei et al. 2014 Azova et al. 2012; Paolillo et al. 2010) . As for its receptors, ET-1 was found to be pro-apoptotic or anti-apoptotic depending on cell type (Ren et al. 2008) .
Taking into account all the above, in the present study, the specific ET A R antagonist (ABT-627) and ET B R antagonist (A-192621) were used to investigate the effect of ET-1 on survival of hVECs.
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Materials and Methods
All methods used for cell isolation and culture, indirect immunofluorescence, confocal microscopy setting, Fura-2 loading, nuclear SYTO-11 staining, solutions, and sources of all compounds, as well as statistical analysis, were the same as those reported previously (Bkaily et al. 1997 (Bkaily et al. , 2008 Avedanian 2010) .
Isolation and culture of vascular endothelial cells
All work was done in accordance with the requirements of the institutional review committee for the use of human material. Human VECs were isolated from non-diseased aortas of healthy donors (16-45 years old) supplied by Quebec Transplant. The freshly isolated and cultured aortic endothelial cells used in this study originated from at least 3 different donors and at low passages (2-4). Briefly and as previously described (Bkaily et al. 1997 (Bkaily et al. , 2008 Avedanian et al. 2010) , the aortas were placed for 15 min in M199 medium (Gibco-BRL, Burlington, Ont.) containing antibiotics and 0.1% (50 U/mL) collagenase. Next, the medium was replaced by a fresh, collagenase-free M199 solution containing antibiotics. The VECs were then gently scraped with a sterile scalpel blade and the cell-containing medium was collected and centrifuged. Cells were resuspended and cultured in a medium composed of M199 medium containing 10% fetal bovine serum and 50 IU/mL penicillin-G-potassium (Ayrest, Toronto, Ont.). A routine check of quality and purity of the hVECs was done using specific probes as indicated elsewhere (Bkaily et al. 1997; Avedanian et al. 2010) . The aortic hVECs derivation was also confirmed by assessing the presence of the Von Willebrand factor (Bkaily et al. 1997; Avedanian et al. 2010 (Bkaily et al. 1997; Avedanian et al. 2010) .
Annexin V labeling
The Annexin V labeling was performed according to the protocol provided with "Annexin-V-fluos Staining Kit" (Roche Applied Science). Briefly, hVECs were cultured on 25 mm round cover slips until they reach the desired confluence (~ 70 %) and then the cells were treated according to each protocol. The extracellular medium in each Petri dish was then injected with 75 µl of the Annexin-V-Fluos working solution prepared by mixing 20 µl of stock probe in 1 ml of incubation buffer. The cells were incubated in the presence of the probe for 30 min at room temperature. The coverslips were then observed by a confocal microscope using the 488-nm wavelength line.
Terminal deoxynucleotidyl transferase dUTP mediated nick end labeling (TUNEL)
The in situ TUNEL technique was performed according to the protocol provided with the "ApopTag fluorescein in situ detection kit" (Cedarlane Laboratories limited, Ontario, CA) with some modifications (Beauséjour et al. 2013) . Briefly, cultured hVECs (on 12-well plates) were fixed with a 2% formaldehyde/phosphate buffer (0.2 M Na 2 HPO 4 pH 7.4) for 45 min at 4°C. The fixation reaction was stopped by quenching with PBS-glycine (150 mM pH 7.2) for 15 min at RT. The cells were then permeabilized with a fresh 0.1%
PBS-Triton-X-100 solution for 3 min at RT. The non-specific sites were blocked with a non-fat dried milk (NFDM) (10%) solution containing Na + -azide followed by incubation with an equilibrium buffer for 5 min at RT. 
Assessment of Apoptosis
After obtaining the images from confocal microscopy (for Annexin V) and fluorescence microscopy (for TUNEL), the number of total and apoptotic cells was counted, in five different fields of vision, in order to obtain a minimum of 500 cells per treatment. After that, the percentage of apoptotic cells to total number of cells was calculated for control and treated conditions.
Indirect immunofluorescence for ET B R
The protocol for indirect immunofluorescence was previously described (Avedanian et al. 2010) . In brief, aortic hVECs were fixed for 10 min in ice cold 4% paraformaldehyde followed by washing with PBS 1X. The cells were then incubated for 10 min with PBS D r a f t containing sodium borohydride (2 mg/mL), permeabilized and blocked with 0.1% Triton X-100, 7% normal serum (NS), and 5% non-fat dry milk (NFDM) for 30 min. Finally, the cells were washed twice in PBS and incubated overnight at 4 °C with PBS containing 1.4% NS, 1% NFDM, and 0.1% Triton X-100 in the presence of a rabbit polyclonal anti-ET B antibody (1/200) (Alamone labs, Jerusalem, Israel). After two PBS washes, the cells were incubated for 1 h at room temperature with the same buffer as the primary antibody in addition to an anti-rabbit secondary antibody coupled to Alexa Fluor 488 (1 µg/mL) (Molecular Probes, Eugene, Ore.). The cells were examined using 3D imaging confocal microscopy.
Indirect immnofluorescence for caspase 3
Briefly, cultured hVECs were fixed with paraformaldehyde (2% in PBS 1X) for 45 min 
Confocal microscopy
Cells were examined with a Molecular Dynamics (Sunnyvale, Calif.) Multi Probe 2001 confocal argon laser scanning (CSLM) system equipped with a Nikon Diaphot epifluorescence inverted microscope and a 60× (1.4 NA) Nikon Oil Plan achromat objective as described previously (Bkaily et al. 1997 (Bkaily et al. , 2017 . In brief, the 488 nm argon laser line (9.0 mV) was directed to the sample via a 510 nm primary dichroic filter and attenuated with a 1% to 3% neutral density filter to reduce photobleaching. Pinhole size was set at 100 µm. The image size was set at 512 pixels × 512 pixels with a pixel size of 0.34 µm. Laser line intensity, photometric gain, PMT settings, and filter attenuation were kept rigorously constant throughout the experimental procedures. For each sample, 16 to 20 sections were recorded covering the entire volume of the cell and constituting a 3D serial section. At the end of each experiment, the nucleus was stained with 100 nmol/L of live cell nucleic acid stain SYTO-11 (Molecular Probes, Eugene, Ore.) as described previously (Bkaily et al. 1997 (Bkaily et al. , 2017 . Scanned images were transferred onto a Silicon and maximum intensity in white.
Volume rendering and fluorescence intensity measurement
Measurement of receptor or protein densities within the cytosol and nucleus was performed on quantitative real 3D images as described previously (Bkaily et al. 1997 (Bkaily et al. , 2017 . In brief, the nuclear area following SYTO-11 staining was isolated from the rest of the cell by setting a lower intensity threshold filter to confine relevant pixels. A 3D binary image series of the nuclear volume was then generated for each cell using the exact same x, y, and z set planes. By applying these binary image patterns of the nucleus to the same cell but labeled for the peptide or the receptors (the binary image serves a cookie cutter), a new 3D projection was created depicting fluorescence intensity levels exclusively within the nucleus. Hence, by removing the nucleus from the surrounding cytoplasm, we were then able to measure mean fluorescence intensity values in the entire nuclear or cytosolic volume.
Western blot
Extraction of proteins to be used for Western blot was performed using the same protocol For each western blot, in order to insure that the quantities of proteins loaded in the wells are equivalent, a control was obtained where the membrane was incubated for 30 min at RT with a mouse monoclonal anti-β-actin antibody (dilution 1/3000).
Densitometry
In order to quantify the levels of protein expression, densitometric analyses were performed using the MCID Basic-M5 
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Results
Effect of ET-1 and its receptors on apoptosis induced by genistein
In this series of experiments, we wanted to study the effect of ET-1 and its receptors on genistein-induced apoptosis in hVECs using two complementary methods namely Annexin V labeling and in situ TUNEL assays.
In the first series of experiments, cultured hVECs were treated with genistein (300 µM)
for 24 hours in the presence and absence of ET-1 (10 -7 M) or the specific ET B receptor agonist IRL1620 (10 -7 M). Figure 1A -D shows examples and figure 1E summarizes the results. As can be seen in this figure, a 24-hr treatment with genistein induced an apparent increase in the number of cells labeled with annexin V (Fig. 1B ) compared to control (Fig. 1A) . However, in the presence of ET-1 (10 -7 M), treatment with genistein did not cause an apparent change in the number of annexin V-labeled cells (Fig. 1C) compared to control (Fig. 1A) . Similarly, a 24-hr treatment with genistein in the presence of the specific ET B receptor agonist IRL1620 (10 -7 M) had no effect on the number of annexin V-labeled cells (Fig. 1D ) compared to control. Figure 1E shows that there was a significant increase (p<0.001) in the apoptotic index of hVECs (the percentage of annexin V-labeled cells with respect to total number of cells) following genistein treatment for 24 hours compared to control. However, the presence of ET-1 attenuated significantly (p<0.01) the apoptotic index of hVECs. Similarly, in the presence of the ET B R specific agonist IRL1620 the apoptotic index of hVECs was significantly decreased (p<0.01) back to control level.
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In order to identify the ET-1 receptor subtype mediating the anti-apoptotic effect of ET-1, hVECs were treated for 24 hours with genistein in the presence of ET-1 (10 -7 M) and either the ET A R antagonist, ABT-627 (10 -7 M) or the ET B R antagonist, A-192621 (10 -7 M). As figure 1E shows, pretreatment with ET A R antagonist, ABT-627, did not affect the anti-apoptotic effect of ET-1 on genistein-induced apoptosis. In a last series of experiments, the cells were treated with the specific ET B R antagonist A-192621 followed by addition of Et-1 and genistein. As can be seen in figure 1E , blockade of ET B R completely prevented ET-1 from preventing apoptosis induced by genistein.
In the next series of experiments, the same protocols described above were repeated but apoptosis was assessed using in situ TUNEL assays. Similar to ET-1, pre-treatment with the ET B R agonist IRL1620, also significantly (p<0.05) prevented genistein from increasing the apoptotic index. In another series of experiments, the cells were first treated with the ET A R antagonist, ABT627, and then ET-1 and genistein were added for 24 hours. As can be seen, blockade of ET A R did not prevent ET-1 from decreasing the apoptotic index induced by gensitein (p<0.05). In the last series of experiments, pretreatment with the ET B R antagonist, A192621, followed by exposure of the cells to ET-1 and genistein for 24 hours completely prevented ET-1 from preventing genistein from inducing apoptosis of hVECs (Fig. 2M) .
Effect of genistein on ET B R relative density
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In the first series of experiments, we used Western blot in order to determine whether genistein-induced apoptosis was accompanied by changes in total ET B R relative density.
In addition, we verified whether ET-1 or the ET B R agonist IRL1620 (10 -7 M) prevented these changes. Figure 3A shows an example and figure 3B summarizes the results. As seen in this figure, a 24-hr treatment with genistein induced a significant decrease (p<0.01) in ET B R relative density. Neither ET-1 nor the ET B R agonist prevented genistein from significantly decreasing the total ET B R relative density.
In another series of experiments, we used the quantitative 3D imaging technique in order to verify whether the observed decrease of relative ET B R density was at the cytosolic (including plasma membrane, PM) and/or nuclear (including nuclear envelope membranes, NEM) levels. Figure 4A -F shows examples of the effects of genistein and ET-1 and figure 4G summarizes the results. As can be seen in figure 4A , and as expected, the relative density of ET B R in hVECs was very high at the nuclear level and treatment for 24 hours with genistein apparently decreased the relative density of ET B R (Fig. 4C) which is significant only at the nuclear level (Fig. 4G) . Treatment with ET-1 alone induced an increase in ET B R relative density only at the cytosolic (including PM) level (p<0.001) (Fig. 4G) . As can be seen in figure 4E and G, ET-1 prevented the decrease in nuclear (including NEM) ET B R relative density along with increasing the relative density of this type of receptor at the cytosolic level (p<0.01, gensitein vs. ET-1+genistein).
However, treatment with the ET B R agonist did not prevent genistein from inducing a significant decrease in nuclear (including NEM) relative density of ET B R (genistein vs. Our results show that in human VECs, ET-1 promotes survival by preventing apoptosis of this cell type. It is difficult to make a generalization concerning the role of ET-1 in cell survival since it is reported to be pro-apoptotic or anti-apoptotic depending on cell type as well as on the ratio of ET A /ET B receptor subtypes (Ren et al. 2008) . It is worth mentioning that the finding that ET-1 as anti-apoptotic mediator in hVECs is similar to that reported in rat VECs (Shichiri et al. 1997; Jankov et al. 2006) . However, our results
show that the anti-apoptotic effect of ET-1 in hVECs is mediated via activation of ET B R and not ET A R which is different from what is reported in rat VECs (Ren et al. 2008; Jankov et al. 2006 ). In addition, the anti-apoptotic effect of ET B R activation was found to be associated with caspase 3 inhibition. This study looked at caspase-dependent apoptosis (also known as "intrinsic" or "common" or "apoptosome-driven" pathway of apoptosis D r a f t (Kroemer et al. 2009; Vachon, 2011 Bkaily, G., Choufani, S., Avedanian, L., Ahmarani, L., Nader, M., Jacques, D. et al. 231x165mm (300 x 300 DPI)
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